News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boston Scientific Corporation (BSX) (Jobs) Gets Warning Letter



9/10/2007 12:01:35 PM

NEW YORK - Leerink Swann & Co. reaffirmed a "Market Perform" rating for Boston Scientific Corp. Monday, despite the company receiving a warning letter from the Food and Drug Administration for not disclosing deaths in a now canceled drug development program. On Friday, the FDA's warning letter chided Boston Scientific for failing to report two of five deaths in a 43-patient stent trial aimed at treating abdominal aortic aneurysms. The study was abandoned in 2006 after learning that the device had serious problems that resulted in at least 25 stent fractures.

Read at Forbes

Related News

comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES